<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acquired hemophilia A (and other acquired coagulation factor inhibitors)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acquired hemophilia A (and other acquired coagulation factor inhibitors)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acquired hemophilia A (and other acquired coagulation factor inhibitors)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paula James, MD, FRCPC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acquired clotting factor inhibitors are autoantibodies that either inhibit the activity or increase the clearance of a clotting factor. These patients often present with unexplained bleeding and prolonged clotting times. Inhibitors in individuals with congenital hemophilia A and B are due to alloantibodies against infused factor concentrates.</p><p>This topic review discusses evaluation and management of acquired hemophilia A (acquired factor VIII inhibitor) and other acquired clotting factor inhibitors. </p><p>Separate topic reviews discuss the general bleeding evaluation, acquired von Willebrand syndrome (AVWS), and heritable factor deficiencies, including von Willebrand disease (VWD), hemophilia, and inhibitors in people with hemophilia A or B:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding evaluation</strong> – (See  <a class="medical medical_review" href="/d/html/5936.html" rel="external">"Approach to the child with bleeding symptoms"</a> and  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>AVWS</strong> – (See  <a class="medical medical_review" href="/d/html/110531.html" rel="external">"Acquired von Willebrand syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital hemophilia A and B</strong> – (See  <a class="medical medical_review" href="/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhibitors in congenital hemophilia A and B</strong> – (See  <a class="medical medical_review" href="/d/html/1308.html" rel="external">"Inhibitors in hemophilia: Mechanisms, prevalence, diagnosis, and eradication"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>VWD</strong> – (See  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factor XI deficiency</strong> – (See  <a class="medical medical_review" href="/d/html/1333.html" rel="external">"Factor XI (eleven) deficiency"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rare bleeding disorders</strong> – (See  <a class="medical medical_review" href="/d/html/1336.html" rel="external">"Rare inherited coagulation disorders"</a>.)</p><p></p><p class="headingAnchor" id="H4215671480"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H4199952199"><span class="h2">Inhibitors are autoantibodies</span><span class="headingEndMark"> — </span>Acquired clotting factor inhibitors discussed herein are autoantibodies. </p><p>These inhibitors bind the specific clotting factor (typically, factor VIII) and interfere with its function and/or reduce its half-life. In both cases, factor activity is reduced, sometimes to undetectable levels, similar to severe hemophilia. This leads to an increased bleeding risk; serious bleeding is the most common presentation. (See <a class="local">'Typical presentation and clinical findings'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Function-blocking</strong> – Function-blocking antibodies are most common, and they most commonly affect factor VIII. Factor VIII is not an enzyme; when activated by thrombin to factor VIIIa, it acts as a cofactor in the intrinsic tenase complex, functioning as a scaffold to bring together the enzyme factor IXa and the substrate factor X to activate factor X to Xa on the surface of platelets and endothelial cells, via binding to phospholipids. Factor VIII is stabilized by binding to and circulating as a complex with von Willebrand factor (VWF). Acquired factor VIII antibodies interfere with both of these functions [<a href="#rid1">1-3</a>]. (See  <a class="medical medical_review" href="/d/html/1316.html" rel="external">"Biology and normal function of factor VIII and factor IX", section on 'Intrinsic pathway X-ase'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased clearance</strong> – Some antibodies have proteolytic activity and can increase the clearance of the factor [<a href="#rid4">4</a>]. Factor II (prothrombin) antibodies are an example of this mechanism. (See <a class="local">'Other factor inhibitors'</a> below.)</p><p></p><p>Not all circulating antibodies directed against a clotting factor will cause factor deficiency. Various studies have described characteristics of non-inhibitory antibodies [<a href="#rid5">5,6</a>]. </p><p>Pathogenesis of the antibodies has been challenging to determine due to the low incidence and confounding conditions and comorbidities.</p><p>One hypothesis proposed to explain development of postpartum factor VIII inhibitors is that a maternal autoantibody is stimulated by epitopes encoded by the paternal <em>F8 </em>gene that are expressed by the fetus and perhaps introduced into maternal circulation via fetomaternal hemorrhage [<a href="#rid7">7</a>]. If true, pregnancies with female fetuses would be overrepresented (since <em>F8</em> is on the X chromosome, and only female fetuses receive a paternal X chromosome). However, in a review of 12 pregnancies, seven fetuses were male, suggesting this is not a major mechanism of inhibitor stimulation [<a href="#rid7">7</a>].</p><p>Antibody characteristics include [<a href="#rid1">1-4,8-10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Typically immunoglobulin G (IgG); mostly IgG-1 and IgG-4.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyclonal (recognizing several factor VIII epitopes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Do not bind complement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>May proteolyze factor VIII.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For factor VIII inhibitors, directed against the C2 domain of factor VIII, which binds VWF in the circulation and phosphatidylserine on platelet and endothelial cell surfaces, or, less commonly, the A2 domain. (See  <a class="medical medical_review" href="/d/html/1316.html" rel="external">"Biology and normal function of factor VIII and factor IX", section on 'C2 domain'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For factor V inhibitors, directed against the C2 domain, which binds phosphatidylserine on platelet and endothelial cell surfaces [<a href="#rid11">11-13</a>]. </p><p></p><p>Other predisposing factors may include [<a href="#rid4">4,10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Polymorphisms in immune regulatory genes such as <em>CTLA4 </em>or genes that encode HLA antigens. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoreactive T cells.</p><p></p><p class="headingAnchor" id="H310920601"><span class="h2">Underlying conditions for acquired hemophilia A</span><span class="headingEndMark"> — </span>Approximately one-half of individuals with acquired hemophilia A have an associated underlying condition [<a href="#rid14">14,15</a>]. It is unclear whether these conditions cause the inhibitor to develop, trigger expansion of cells producing the inhibitor, or are merely markers of immune dysregulation or autoimmunity. </p><p>Common underlying conditions include [<a href="#rid16">16-24</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy (solid tumors [especially adenocarcinomas] and hematologic malignancies)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmunity or connective tissue disorders (rheumatoid arthritis, systemic lupus erythematosus [SLE])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy or postpartum period (typically within two to three months postpartum, typically following a first pregnancy)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Older age (see <a class="local">'Epidemiology'</a> below)</p><p></p><p>The remainder of patients (approximately one-half) lack an underlying disorder.</p><p>In a pharmacovigilance database study from 2023 involving 185 cases of drug-induced factor VIII inhibitors, the drugs with the strongest association were <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>, and <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a> [<a href="#rid25">25</a>]. Immunomodulatory drugs or other medications (penicillin, sulfonamide, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, clopidogrel) have also been associated with acquired hemophilia A [<a href="#rid25">25-30</a>]. One report identified 12 cases of acquired hemophilia A associated with immune checkpoint inhibitors (<a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>) from 2011 to 2021 [<a href="#rid31">31</a>].</p><p>In a series of 37 pediatric acquired factor inhibitors (mostly to factor VIII), the most common underlying causes were autoimmunity (17 percent), infections (17 percent) and antibiotics, especially penicillin (22 percent) [<a href="#rid32">32</a>].</p><p>The finding of autoantibodies to prothrombin in the setting of a lupus anticoagulant has been termed "lupus anticoagulant hypoprothrombinemia syndrome" (LAHPS) [<a href="#rid33">33</a>]. (See <a class="local">'Other factor inhibitors'</a> below.)</p><p class="headingAnchor" id="H2381040100"><span class="h2">Thrombin and factor V inhibitors after exposure to topical thrombin or fibrin glue</span><span class="headingEndMark"> — </span>Alloantibodies can develop against bovine thrombin or factor V after exposure to <a class="drug drug_general" data-topicid="10285" href="/d/drug information/10285.html" rel="external">topical thrombin</a> or fibrin glue, which contain detectable amounts of bovine factor V [<a href="#rid34">34</a>]. Some individuals develop alloantibodies against both factors; these individuals may also have underlying autoimmunity [<a href="#rid35">35-37</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombin (factor IIa) inhibitors</strong> – Alloantibodies to thrombin (factor IIa) typically occur following exposure to <a class="drug drug_general" data-topicid="10285" href="/d/drug information/10285.html" rel="external">topical thrombin</a> or fibrin glue products, which contain bovine thrombin [<a href="#rid34">34,38-40</a>]. These antibodies do not cause clinical bleeding unless they crossreact with human thrombin [<a href="#rid34">34,39-41</a>]. (See  <a class="medical medical_review" href="/d/html/7938.html" rel="external">"Fibrin sealants"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factor V inhibitors</strong> – Alloantibodies to factor V can also occur after exposure to <a class="drug drug_general" data-topicid="10285" href="/d/drug information/10285.html" rel="external">topical thrombin</a> or fibrin glue because these topical hemostatic agents contain detectable amounts of bovine factor V and the alloantibody to bovine factor V cross-reacts with human factor V [<a href="#rid34">34,39,40,42,43</a>].</p><p></p><p>The availability of human, rather than bovine, thrombin for fibrin sealant and <a class="drug drug_general" data-topicid="10285" href="/d/drug information/10285.html" rel="external">topical thrombin</a> preparations should decrease the incidence of thrombin antibody formation. </p><p class="headingAnchor" id="H1274831211"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Acquired factor inhibitors are rare. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired hemophilia A </strong>– Population reviews of unselected cohorts calculated an incidence of acquired hemophilia A of approximately 1 to 2 per million annually [<a href="#rid44">44-46</a>]. The incidence increases with age [<a href="#rid15">15</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>&lt;16 years: 0.045 per million annually</p><p class="bulletIndent2"><span class="glyph">•</span>&gt;85 years: 14.7 per million annually</p><p></p><p class="bulletIndent1">The age-associated increase likely represents the demographics of underlying conditions associated with these inhibitors [<a href="#rid16">16,47</a>]. An exception is pregnant or postpartum individuals. (See <a class="local">'Underlying conditions for acquired hemophilia A'</a> above.)</p><p></p><p class="bulletIndent1">The female to male ratio for acquired hemophilia A is approximately equal [<a href="#rid18">18,47</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factor II and factor V inhibitors</strong> – Function blocking antibodies to factor II (prothrombin) and factor V are very rare. They can occur after exposure to <a class="drug drug_general" data-topicid="10285" href="/d/drug information/10285.html" rel="external">topical thrombin</a> preparations or topical fibrin glue. (Bovine thrombin prep may also be "contaminated" with bovine FV). (See <a class="local">'Thrombin and factor V inhibitors after exposure to topical thrombin or fibrin glue'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhibitors of other factors</strong> – Inhibitors of other factors are exceedingly rare and generally limited to case reports or small series. (See <a class="local">'Other factor inhibitors'</a> below.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H7"><span class="h2">Typical presentation and clinical findings</span><span class="headingEndMark"> — </span>The hallmark of acquired hemophilia A is bleeding; most series report bleeding as the initial presentation in 80 to 90 percent of individuals [<a href="#rid16">16,18,45</a>]. In a 2023 retrospective series of 34 individuals with acquired hemophilia A followed for 15 years, 33 (97 percent) presented with bleeding [<a href="#rid46">46</a>]. A history of unexplained bleeding was described in 15 (44 percent), emphasizing that diagnostic delays were common. The median interval between bleeding onset and diagnosis in these individuals was four months. The most common cause of the diagnostic delay was failure to obtain an activated partial thromboplastin time (aPTT). </p><p>For other inhibitors, the presentation varies according to the physiologic role of the involved factor (eg, ecchymoses rather than hematomas with an acquired factor XI inhibitor).</p><p>The sudden presence of large hematomas or extensive ecchymoses in an older individual without significant trauma or known bleeding disorder should always raise the clinical suspicion of acquired hemophilia A, and, if an inhibitor of factor VIII is not identified, an inhibitor of a different factor. An approach to the evaluation is presented in the flowchart  (<a class="graphic graphic_algorithm graphicRef141723" href="/d/graphic/141723.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Initial testing (all patients)'</a>.)</p><p>Careful assessment for bleeding sites is important so as not to miss a large hematoma; liters of blood can be lost in retroperitoneal hematomas [<a href="#rid48">48</a>]. This may require imaging such as computed tomography (CT) of the abdomen and pelvis and possibly the thighs.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reason for coming to medical attention</strong> – Most patients present with unexpected bleeding and abnormal clotting tests, typically a prolonged aPTT. The remaining 10 to 20 percent present with an isolated prolonged aPTT without bleeding. Typical factor activity levels and inhibitor titers are listed below. (See <a class="local">'Laboratory testing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient characteristics</strong> – Most individuals are adults, often older. The prevalence of an underlying condition that alters immunity (cancer, autoimmune disorder, postpartum state) varies from approximately 30 to 50 percent [<a href="#rid46">46</a>]. (See <a class="local">'Underlying conditions for acquired hemophilia A'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhibitor characteristics</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Target </strong>– Most acquired factor inhibitors are directed against factor VIII. </p><p></p><p class="bulletIndent2">In a 2010 review of acquired hemophilia in 37 children, 28 (76 percent) were directed against factor VIII; six (16 percent) were against factor IX; two (5 percent) were against factor XI; and one had inhibitors to factor VIII and IX [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Titer </strong>– In a review from the European Acquired Hemophilia (EACH2) Registry (501 patients with acquired hemophilia A), the median titer was 13 Bethesda units (BU); 45 percent had titers of 0 to 10 BU, and 12 percent had titers &gt;100 BU [<a href="#rid18">18</a>]. (See <a class="local">'Inhibitor screen and titer'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleed characteristics </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing</strong> – Most bleeds occur spontaneously; in some cases, bleeding is first noted during or after a surgical procedure [<a href="#rid18">18</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Location</strong> – Subcutaneous bleeding is the most common finding, seen in as many as 80 percent of cases [<a href="#rid14">14</a>]. Visceral bleeding is also common, including retroperitoneal or muscle hematomas  (<a class="graphic graphic_table graphicRef77834" href="/d/graphic/77834.html" rel="external">table 1</a>). These may be challenging to appreciate as a retroperitoneal or thigh hematoma can accommodate several units of blood before a mass appears. Symptomatic patients often present with large hematomas, extensive ecchymoses or severe mucosal bleeding, including epistaxis, gastrointestinal bleeding, and/or gross hematuria. </p><p></p><p class="bulletIndent2">Hemarthroses, which are common in hemophilia A and B, are unusual with acquired factor inhibitors.</p><p></p><p class="bulletIndent2">In a 2021 systematic review of postpartum acquired hemophilia A that identified data for the bleeding pattern in 150 individuals, the most common bleeding sites were obstetric (43 percent), cutaneous (41 percent), and intramuscular (37 percent) [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severity</strong> – Bleeding is often severe, constituting a <strong>medical emergency</strong>. In one of the larger surveys (215 patients), 87 percent experienced major bleeding and 22 percent died from complications attributed directly or indirectly to the inhibitor [<a href="#rid16">16</a>]. In the United Kingdom cohort, bleeding was the cause of death in 9 percent and remained a risk until the inhibitor had been eradicated [<a href="#rid45">45</a>]. In another cohort of 34 patients, fatal bleeding occurred in 6 percent [<a href="#rid46">46</a>]. A significant number of patients have repeat bleeding after initial therapy.</p><p></p><p class="headingAnchor" id="H3284287383"><span class="h2">Laboratory testing</span></p><p class="headingAnchor" id="H9"><span class="h3">Coagulation tests and factor assays</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prolonged aPTT</strong> – Most factor VIII inhibitors are characterized by a prolonged aPTT and a normal prothrombin time (PT). </p><p></p><p class="bulletIndent1">All possible causes of a prolonged aPTT should be reviewed, including factor deficiencies (factors VIII, IX, XI) and, indirectly, deficiency of von Willebrand factor (VWF), which stabilizes factor VIII, as well as heparin, direct thrombin inhibitors (<a class="drug drug_general" data-topicid="8765" href="/d/drug information/8765.html" rel="external">argatroban</a>, <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>) and sometimes direct factor Xa inhibitors (<a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>)  (<a class="graphic graphic_table graphicRef79969" href="/d/graphic/79969.html" rel="external">table 2</a>). A prolonged aPTT is also seen with antiphospholipid antibodies (aPL) in the antiphospholipid syndrome (APS), but most of these patients do not have an increased bleeding risk; APS increases the risk of thrombosis. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Patient with bleeding'</a>.)</p><p></p><p class="bulletIndent1">In hospitalized patients, a reasonable first step is to exclude the use of heparin as a cause of a prolonged aPTT by repeating the aPTT from a fresh venipuncture (not using a central venous catheter or port)  (<a class="graphic graphic_algorithm graphicRef141723" href="/d/graphic/141723.html" rel="external">algorithm 1</a>). If this cannot be done, a thrombin time and reptilase time can be obtained; heparin prolongs the thrombin time but not the reptilase time. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Activated partial thromboplastin time (aPTT)'</a>.)</p><p></p><p class="bulletIndent1">Subsequent testing depends on the clinical setting. A mixing study and factor VIII activity are both required. Usually, the mixing study results are available first. For serious bleeding, these should be obtained simultaneously. In a nonbleeding patient they can be obtained sequentially. It is also reasonable to rule out acquired von Willebrand syndrome (AVWS), although the clinical presentation of AVWS is usually with mucosal bleeding rather than hematomas. (See  <a class="medical medical_review" href="/d/html/110531.html" rel="external">"Acquired von Willebrand syndrome", section on 'Typical presentations'</a>.)</p><p></p><p class="bulletIndent1">Other causes of a prolonged aPTT with normal PT include deficiencies and inhibitors of other intrinsic pathway factors (IX, XI, XII), lupus anticoagulants, and heparin. Lupus anticoagulants typically affect levels of multiple factors if checked. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Causes of prolonged aPTT'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prolonged TT</strong> – Patients with antibodies against bovine thrombin have a prolonged thrombin time (TT) when bovine reagent thrombin is used in the assay and a normal TT when the thrombin reagent is of human origin. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Thrombin time (TT)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other laboratory findings</strong> – Patients with antibodies against factor V have a prolonged aPTT and PT [<a href="#rid39">39,40</a>]. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests"</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h3">Inhibitor screen and titer</span><span class="headingEndMark"> — </span>The next step after identifying a prolonged aPTT is to determine whether it is due to an inhibitor  (<a class="graphic graphic_algorithm graphicRef141723" href="/d/graphic/141723.html" rel="external">algorithm 1</a>). This is done using a mixing study or inhibitor screen. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Use of mixing studies'</a>.)</p><p>A mixing study is usually easier to obtain than a factor activity level. In a mixing study, equal amounts of patient plasma and control plasma (a 50:50 mix) are mixed and the aPTT (or other clotting test) repeated. If an inhibitor is present, the aPTT remains prolonged. If there is no inhibitor, the amount of factor in the control plasma will be sufficient to correct the aPTT to the normal range. </p><p>In acquired hemophilia A, the inhibitor is typically time and temperature dependent, and the initial 50:50 mix may show normalization of the aPTT. Thus, it is important that the aPTT be performed both immediately after mixing and after two hours (and warmed to 37°C), as some inhibitors take time to bind and inhibit factor activity [<a href="#rid50">50</a>]. </p><p>A mixing study that shows failure to correct the aPTT confirms that an inhibitor is present but does not determine the inhibitor's specificity. The next step is adding a source of phospholipid to the mixed plasma. Correction of the aPTT suggests the presence of antiphospholipid antibodies, which are typically associated with thrombosis rather than bleeding. (See  <a class="medical medical_review" href="/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome", section on 'Antiphospholipid antibodies'</a>.)</p><p>If the aPTT does not correct, the Bethesda assay is performed. The Bethesda assay both establishes the diagnosis of a factor VIII inhibitor and quantifies the antibody titer [<a href="#rid51">51</a>]. </p><p>In the Bethesda assay, the factor VIII activity level is measured, followed by measuring the factor VIII activity on serial dilutions of patient plasma incubated with pooled control plasma at 37°C for two hours. The titer is the reciprocal dilution of patient plasma that results in 50 percent factor VIII activity. One BU is the amount of inhibitor that inhibits all of the factor VIII in 1 mL of blood. An inhibitor titer of 5 BU is considered high because it means the inhibitor in 1 mL of blood can inhibit the factor VIII from 5 mL of blood. The stronger the inhibitor, the higher the BU titer.</p><p>In the EACH2 Registry (501 patients with acquired hemophilia A), the median inhibitor titer was 13 BU/mL, distributed as follows [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>0 to 10 BU/mL: 45 percent of patients</p><p class="bulletIndent1"><span class="glyph">●</span>11 to 100 BU/mL: 43 percent of patients </p><p class="bulletIndent1"><span class="glyph">●</span>101 to 1000 BU/mL: 12 percent of patients</p><p></p><p>The kinetics of inhibitor binding are complex with acquired factor VIII inhibitors, leading to an underestimation of the inhibitor titer by the Bethesda assay, and the inhibitor titer cannot be used to predict bleeding risk [<a href="#rid52">52</a>].</p><p>An enzyme-linked immunosorbent assay (ELISA)-based immunoassay for anti-factor VIII antibodies has also been investigated [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H2118172111"><span class="h3">Factor VIII activity level</span><span class="headingEndMark"> — </span>For individuals with severe or active bleeding, factor VIII activity level should be obtained without delay  (<a class="graphic graphic_algorithm graphicRef141723" href="/d/graphic/141723.html" rel="external">algorithm 1</a>). In most institutions, factor activity levels have a longer turnaround time than mixing studies. For nonbleeding patients, factor VIII activity can be obtained once the mixing study shows failure to correct with a 50:50 mix, but both are needed. </p><p>If factor VIII activity is normal, activity levels of other factors can be obtained (for a prolonged aPTT, factor IX, factor XI, and factor XII).</p><p class="bulletIndent1">In the largest series of acquired hemophilia A (the EACH2 Registry, with 501 patients), the median factor VIII activity was 2 percent, distributed as follows [<a href="#rid18">18</a>]:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activity &lt;1 percent: 18 percent of patients</p><p class="bulletIndent1"><span class="glyph">●</span>Activity 1 to 5 percent: 58 percent of patients</p><p class="bulletIndent1"><span class="glyph">●</span>Activity 5 to 50 percent: 24 percent of patients</p><p></p><p>If factor VIII deficiency is documented (activity below the lower limit of the reference range), the next step is to perform an inhibitor screen. (See <a class="local">'Inhibitor screen and titer'</a> above.)</p><p class="headingAnchor" id="H1993372926"><span class="h2">Confirmed diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of an acquired factor inhibitor is confirmed by the finding of factor activity level below the reference range accompanied by an inhibitor in the appropriate clinical setting (typically, bleeding in a patient without a prior bleeding disorder; less commonly, new onset prolonged clotting times without bleeding).</p><p>Features that are <strong>not</strong> consistent with acquired hemophilia A include:</p><p class="bulletIndent1"><span class="glyph">●</span>Positive family history of hemophilia</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic bleeding disorder since childhood or young adulthood</p><p class="bulletIndent1"><span class="glyph">●</span>History of thrombosis rather than bleeding</p><p class="bulletIndent1"><span class="glyph">●</span>Normal coagulation testing</p><p class="bulletIndent1"><span class="glyph">●</span>Low von Willebrand factor (VWF) activity</p><p></p><p class="headingAnchor" id="H4282355370"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of acquired factor inhibitors includes other acquired or heritable bleeding disorders and other causes of prolonged clotting tests.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired bleeding disorders</strong> – Other acquired bleeding disorders include disseminated intravascular coagulation, acquired von Willebrand syndrome, and various causes of thrombocytopenia. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a> and  <a class="medical medical_review" href="/d/html/110531.html" rel="external">"Acquired von Willebrand syndrome"</a> and  <a class="medical medical_review" href="/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Like acquired hemophilia A or other acquired clotting factor inhibitors, bleeding may be acute and severe, and the patient may have comorbidities such as cancer, surgery, or autoimmunity. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unlike acquired factor inhibitors, these other disorders do not have factor deficiency due to a specific factor inhibitor (typically against factor VIII).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heritable bleeding disorders</strong> – Heritable bleeding disorders include hemophilia, von Willebrand disease, rare factor disorders, and vascular disorders such as hereditary hemorrhagic telangiectasia (HHT) or Ehlers-Danlos syndrome. (See  <a class="medical medical_review" href="/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia"</a> and  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease"</a> and  <a class="medical medical_review" href="/d/html/1336.html" rel="external">"Rare inherited coagulation disorders"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Like acquired factor inhibitors, these disorders are associated with bleeding and may have coagulation test abnormalities.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unlike acquired factor inhibitors, these disorders have specific diagnostic tests and do not have a factor inhibitor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prolonged PT or aPTT</strong> – Other causes of prolonged clotting times include anticoagulants, vitamin K deficiency, and a lupus anticoagulant caused by antiphospholipid antibodies (aPL). (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Evaluation of abnormal results'</a> and  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Lupus anticoagulant tests'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Like acquired factor inhibitors, lupus anticoagulants prolong the aPTT. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unlike acquired factor inhibitors, lupus anticoagulants do not cause bleeding (unless there is a lupus anticoagulant hypoprothrombinemia syndrome [LAHPS]). (See <a class="local">'Underlying conditions for acquired hemophilia A'</a> above.)</p><p></p><p class="headingAnchor" id="H1571149084"><span class="h2">Post-diagnostic testing</span><span class="headingEndMark"> — </span>Testing to identify an underling condition is generally limited to a thorough physical examination and age-appropriate cancer screening. Aggressive testing for malignancy in the absence of suggestive findings is not supported by available evidence. </p><p class="headingAnchor" id="H13"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Initial treatment of acquired factor inhibitors typically requires [<a href="#rid14">14-16,52,54-63</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Control of bleeding – (See <a class="local">'Control bleeding'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Elimination of the inhibitor – (See <a class="local">'Eliminate the inhibitor'</a> below.)</p><p></p><p>Patients should be managed by, or in consultation with, a bleeding disorders expert, even if they present without overt bleeding, due to the risk of life-threatening bleeding and the challenges in determining the best therapy [<a href="#rid55">55</a>].</p><p>As with any other bleeding disorder, elective invasive procedures should be postponed, necessary procedures should be done with appropriate support, injuries should be avoided, and anticoagulants and antiplatelet agents should be avoided or minimized [<a href="#rid14">14,64</a>]. </p><p class="headingAnchor" id="H14"><span class="h2">Control bleeding</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach (all acquired factor inhibitors)</strong> – Active bleeding may be treated with one or more of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bypassing products such as recombinant activated factor VII (rFVIIa) or factor eight inhibitor bypassing activity (FEIBA).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Factor concentrates, such as factor VIII (human or porcine) for acquired hemophilia A, as long as the inhibitor titer is low.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fresh Frozen Plasma (FFP) or prothrombin complex concentrate (PCC), only if a factor concentrate is not available and the inhibitor titer is low.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antifibrinolytic agents for mucosal bleeding.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="115772" href="/d/drug information/115772.html" rel="external">Emicizumab</a> for acquired hemophilia A (off-label use).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Platelet transfusions for factor V inhibitors.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>DDAVP (<a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>) for acquired hemophilia A in the rare situation where the inhibitor titer is &lt;5 BU and a threefold increase in factor VIII activity would be considered sufficient to treat bleeding. </p><p></p><p class="bulletIndent1">All decisions should be made in consultation with a bleeding disorders expert, who can assess the severity of bleeding, titer of the inhibitor, and optimal therapy from among available options at the institution. Some individuals may benefit from transfer to a tertiary center with more resources and expertise. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired hemophilia A-specific guidance</strong> – A 2020 International Guideline for treating acquired hemophilia A recommended a bypassing agent or <a class="drug drug_general" data-topicid="97772" href="/d/drug information/97772.html" rel="external">recombinant porcine factor VIII</a> over human factor VIII products (recombinant or plasma-derived) [<a href="#rid14">14</a>]. A 2023 consensus recommendation from the Gesellschaft für Thrombose und Hämostaseforschung (GTH) based on input from 33 experts from German and Austrian hemophilia care centers expressed a strong consensus that <a class="drug drug_general" data-topicid="115772" href="/d/drug information/115772.html" rel="external">emicizumab</a> is effective prophylaxis against bleeding and should be considered or offered at the time of diagnosis [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">The flowchart illustrates an approach to selecting therapy based on the inhibitor titer  (<a class="graphic graphic_algorithm graphicRef141724" href="/d/graphic/141724.html" rel="external">algorithm 2</a>). </p><p></p><p class="headingAnchor" id="H820622310"><span class="h3">Serious bleeding</span><span class="headingEndMark"> — </span>Serious bleeding includes life-threatening bleeding (into a closed space) or bleeding that would result in transfusion.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>High titer inhibitor (≥5 Bethesda units) and severe bleeding</strong> – Options include  (<a class="graphic graphic_algorithm graphicRef141724" href="/d/graphic/141724.html" rel="external">algorithm 2</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bypassing agents</strong> – These are clotting factor products that contain activated factor VIIa, which bypasses the function of factors VIII and IX in the clotting cascade. Dosing is similar to people with hemophilia and inhibitors, as discussed separately.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>FEIBA (factor VIII inhibitor bypassing activity)</strong> – This is a PCC from plasma that contains factor VIIa along with factors II, IX, and X  (<a class="graphic graphic_table graphicRef94210" href="/d/graphic/94210.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B", section on 'Bypassing products (rFVIIa products or FEIBA)'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Recombinant activated factor VII (rFVIIa) </strong>– There are two brands with different dosing and indications. (See  <a class="medical medical_review" href="/d/html/1341.html" rel="external">"Recombinant factor VIIa: Administration and adverse effects", section on 'Available products and their properties'</a>.)</p><p></p><p class="bulletIndent2">There are no comparative trials to determine whether an activated PCC such as FEIBA or rFVIIa is more effective in patients with a high titer inhibitor and active bleeding. Results from an uncontrolled European registry in 501 patients with acquired hemophilia A suggest that FEIBA and rFVIIa have similar efficacy [<a href="#rid61">61</a>]. The choice between them should be guided by local experience and cost considerations. Of the two, FEIBA is likely to be less expensive.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Emicizumab</strong> <strong>for factor VIII inhibitors </strong>– <a class="drug drug_general" data-topicid="115772" href="/d/drug information/115772.html" rel="external">Emicizumab</a> is a bispecific monoclonal antibody that substitutes for the function of factor VIII; it is used for bleed prophylaxis in congenital hemophilia A  (<a class="graphic graphic_figure graphicRef107801" href="/d/graphic/107801.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis", section on 'Emicizumab for hemophilia A'</a>.)</p><p></p><p class="bulletIndent2">Consensus recommendations state that <a class="drug drug_general" data-topicid="115772" href="/d/drug information/115772.html" rel="external">emicizumab</a> is effective and should be considered or offered to patients with acquired hemophilia A [<a href="#rid65">65</a>]. </p><p></p><p class="bulletIndent2">For high risk of bleeding, an accelerated regimen uses a loading dose of 6 mg/kg on day 1, followed by 3 mg/kg on day 2, followed by a maintenance dose of 1.5 mg/kg once per week [<a href="#rid65">65</a>]. For lower bleeding risk, 3 mg/kg once per week for four weeks can be considered. Due to concerns about thrombotic microangiopathy, breakthrough bleeding in patients receiving <a class="drug drug_general" data-topicid="115772" href="/d/drug information/115772.html" rel="external">emicizumab</a> should be treated with rFVIIa or <a class="drug drug_general" data-topicid="97772" href="/d/drug information/97772.html" rel="external">recombinant porcine factor VIII</a> but not with FEIBA.</p><p></p><p class="bulletIndent2">Experience with <a class="drug drug_general" data-topicid="115772" href="/d/drug information/115772.html" rel="external">emicizumab</a> for acquired hemophilia A is limited to small trials and series. In a study involving 47 individuals with acquired hemophilia A treated with emicizumab, the mean breakthrough bleeding rate was 0.04 bleeds per patient-week; 33 patients (70 percent) had no bleeding events [<a href="#rid66">66</a>]. Smaller series have demonstrated good efficacy with low rates of breakthrough bleeding [<a href="#rid67">67-69</a>]. No major treatment emergent adverse events have been documented.</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="115772" href="/d/drug information/115772.html" rel="external">Emicizumab</a> is not effective for inhibitors to factors other than factor VIII.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Platelet transfusion for factor V inhibitors</strong> – Platelet transfusions can be used to treat severe bleeding with acquired factor V inhibitors. Platelets do not contain appreciable levels of other coagulation factors other than factor V. (See <a class="local">'Other factor inhibitors'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Porcine factor VIII for factor VIII inhibitors </strong>– Porcine (pig) factor VIII (susoctocog alfa; Obizur) has differences in protein sequence from human factor VIII and may undergo less inactivation by the inhibitor. The dose is 200 international units/kg, with dose and frequency titrated to maintain the desired factor VIII activity level [<a href="#rid70">70</a>]. Availability may be limited. Details of administration are discussed separately. (See  <a class="medical medical_review" href="/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B", section on 'Recombinant porcine factor VIII (hemophilia A)'</a>.)</p><p></p><p class="bulletIndent2">In a prospective study in 28 patients with acquired hemophilia A and severe bleeding, porcine factor VIII controlled bleeding by 24 hours in all 28 and was ultimately considered successful in 24 individuals (86 percent) [<a href="#rid62">62</a>]. Efficacy was greater in those who received porcine factor VIII as primary therapy versus those who received another hemostatic agent first (94 versus 73 percent). All individuals also received immunosuppressive therapy. There were no serious adverse events. </p><p></p><p class="bulletIndent2">Recombinant ovine (sheep) factor VIII is also being investigated [<a href="#rid71">71</a>]. Porcine or ovine factor VIII has no role in treating inhibitors other than factor VIII.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other supplements</strong> – Additional agents listed below for less-severe bleeding (DDAVP, antifibrinolytic agents) may also be used if considered helpful. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low titer inhibitor and severe bleeding</strong> – Bypassing agents may be reasonable, as discussed above.</p><p></p><p class="bulletIndent1">Individuals with inhibitors with titers &lt;5 Bethesda units (BU) also may derive benefit from standard clotting factor administration  (<a class="graphic graphic_algorithm graphicRef141724" href="/d/graphic/141724.html" rel="external">algorithm 2</a>). Recombinant and plasma-derived factor VIII products are available; these products are generally considered interchangeable for treating severe bleeding. However, large amounts of factor VIII may be needed to overcome the inhibitor, even if the titer is low.</p><p></p><p class="bulletIndent1">The amount of factor VIII required depends on the inhibitor titer. As an example, the patient can receive 40 units/kg plus 20 units/kg for each Bethesda unit of the inhibitor. Factor VIII activity is checked 10 minutes following administration, and repeat doses administered if the incremental recovery is inadequate. Details of dosing are determined in consultation with a hemostasis expert. (See  <a class="medical medical_review" href="/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B", section on 'Factor dosing for severe bleeding (patients without inhibitors)'</a>.)</p><p></p><p class="bulletIndent1">Individuals with low titer inhibitors may also be treated with the products listed above for high titer inhibitors.</p><p></p><p class="headingAnchor" id="H2824150267"><span class="h3">Less-severe bleeding</span><span class="headingEndMark"> — </span>Options include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifibrinolytic agents</strong> – <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">Tranexamic acid</a> or epsilon <a class="drug drug_general" data-topicid="8561" href="/d/drug information/8561.html" rel="external">aminocaproic acid</a> may be used, especially for mucosal bleeding. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DDAVP </strong>– DDAVP (<a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a>) increases release of factor VIII from platelets and endothelial cells. It is used for mild hemophilia A and can be used in acquired hemophilia, but the increase in factor VIII activity is relatively small (twofold over baseline) and this would not be sufficient to overcome a high-titer inhibitor. Factors other than factor VIII and von Willebrand factor are not stored in these cells and therefore not increased with DDAVP. The DDAVP dose is 0.3 mcg/kg subcutaneously or intravenously per day for three to five days. Tachyphylaxis occurs and repeated dosing beyond three to five days is unlikely to provide further benefit. DDAVP can cause hyponatremia, seizures, and possibly an increased risk of thrombosis.</p><p></p><p class="headingAnchor" id="H167535692"><span class="h3">Not actively bleeding</span><span class="headingEndMark"> — </span>Individuals who do not have active bleeding generally do not require hemostatic products as long as they are not undergoing invasive procedures. Elimination of the inhibitor should be pursued as appropriate. (See <a class="local">'Eliminate the inhibitor'</a> below.)</p><p class="headingAnchor" id="H15"><span class="h2">Eliminate the inhibitor</span><span class="headingEndMark"> — </span>Most patients are treated with immunosuppression to eliminate (or speed the resolution) of the inhibitor, as illustrated in the flowchart  (<a class="graphic graphic_algorithm graphicRef141724" href="/d/graphic/141724.html" rel="external">algorithm 2</a>). This is especially true for patients with active bleeding or a history of serious bleeding associated with the inhibitor. For selected individuals without bleeding who have a low inhibitor titer, it may be possible to observe without immunosuppression.</p><p class="headingAnchor" id="H3472459872"><span class="h3">Indications for immunosuppression and choice of regimen</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deciding to start immunosuppression</strong> – Any individual with an acquired factor inhibitor and bleeding is at risk for life-threatening consequences and should receive immunosuppression to decrease the inhibitor and reduce the risk of further bleeding. </p><p></p><p class="bulletIndent1">Immunosuppression is also appropriate for most individuals with acquired factor inhibitors and prolonged clotting times that indicate increased bleeding risk. An exception is the lupus anticoagulant phenomenon due to antiphospholipid antibodies, which is an in vitro phenomenon that may be seen in antiphospholipid syndrome, a prothrombotic rather than bleeding syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of regimen</strong> – The choice of regimen is individualized, taking into account the titer of the inhibitor and how rapidly inhibitor elimination is required  (<a class="graphic graphic_algorithm graphicRef141724" href="/d/graphic/141724.html" rel="external">algorithm 2</a>). <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">Prednisone</a> alone is the easiest to manage but can take longer than prednisone plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> in an individual with a higher titer inhibitor. High quality evidence comparing different immunosuppressive regimens is lacking. (See <a class="local">'Supporting evidence for immunosuppressive regimens'</a> below.) </p><p></p><p class="bulletIndent1">A 2020 International Guideline recommended stratifying regimen choice for acquired hemophilia A by factor VIII activity level and inhibitor titer [<a href="#rid14">14</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Factor VIII activity ≥1 international unit/dL and inhibitor titer ≤20 Bethesda units (BU) – Glucocorticoid alone.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Factor VIII activity &lt;1 international unit/dL or inhibitor titer &gt;20 BU – Cytotoxic therapy (eg, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>) plus a glucocorticoid or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> plus a glucocorticoid.</p><p></p><p class="bulletIndent1">In both cases, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> is added if there is no evidence of response by three to four weeks [<a href="#rid14">14</a>]. This is consistent with our practice. This guideline predates the evidence supporting combination therapy with cyclophosphamide, decadron, and rituximab (CyDRi), which is also an option. (See <a class="local">'Dosing and duration of specific regimens'</a> below.)</p><p></p><p class="bulletIndent1">A 2012 report of 449 individuals in the Acquired Haemophilia Registry (EACH2) found the following distribution of therapies [<a href="#rid18">18</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Glucocorticoid alone: 268 patients (60 percent) </p><p class="bulletIndent2"><span class="glyph">•</span>Cytotoxic agent plus glucocorticoid: 130 patients (29 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Other combinations: 51 patients (11 percent) </p><p class="bulletIndent2"><span class="glyph">•</span>Rituximab alone: 15 patients (3 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Cytotoxic therapy alone: 7 patients (2 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasmapheresis as a temporizing measure</strong> – Plasmapheresis may be used to deplete the inhibitor while waiting for immunosuppression to take effect. Inhibitor depletion may last for days to weeks in some cases. Plasmapheresis can also be used for refractory disease. (See <a class="local">'Treatment of relapse or refractory disease'</a> below.)</p><p></p><p class="headingAnchor" id="H3004920813"><span class="h3">Dosing and duration of specific regimens</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single agent glucocorticoid</strong> – <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">Prednisone</a> 1 mg/kg/day orally or equivalent dose of parenteral glucocorticoid until the inhibitor has resolved and the factor VIII activity is in the normal range (often &gt;6 weeks), although it may be reasonable to switch to a different agent earlier if there is no response. [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid plus </strong><strong>rituximab</strong> – <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">Methylprednisolone</a> 0.8 mg/kg per day for the first three weeks and then tapered; plus one dose of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, 375 mg/m<sup>2</sup>; on day 1 [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single agent </strong><strong>cyclophosphamide</strong> – <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> can be given at a dose of 1.5 to 2 mg/kg/day orally [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mycophenolate</strong><strong> mofetil (MMF)</strong> – MMF can be given at a dose of 1 g/day orally for one week, followed by 2 g/day [<a href="#rid14">14</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IVIG</strong> – Intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) can be given as 1 g/kg daily for two days or 400 mg/kg daily for five days [<a href="#rid73">73</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CyDRi</strong> – <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (CyDRi) is a combination regimen using cyclophosphamide 1000 mg on days 1 and 22, dexamethasone 40 mg on days 1, 8, 15, and 22, and rituximab 100 mg on days 1, 8, 15, and 22 [<a href="#rid74">74</a>]. If necessary, this can be repeated until remission, no sooner than day 43 of the previous cycle. </p><p></p><p>If the factor activity is increasing and/or inhibitor titer is decreasing, it may be prudent to continue therapy or provide additional cycles of therapy rather than changing to a new agent. If there is no response, it may be reasonable to change to a new agent.</p><p>Rarely, an individual may have a persistent factor inhibitor that cannot be eradicated but can be controlled with intermittent cytotoxic therapy and/or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> when the titer increases. (See <a class="local">'Treatment of relapse or refractory disease'</a> below.)</p><p class="headingAnchor" id="H1074319352"><span class="h3">Supporting evidence for immunosuppressive regimens</span><span class="headingEndMark"> — </span>Randomized trials comparing one regimen with another are very limited. Evidence mostly comes from observational studies.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prednisone</strong><strong> and/or </strong><strong>cyclophosphamide</strong> – In retrospective studies, individuals treated with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus glucocorticoids appear to have better responses and greater toxicity than those treated with glucocorticoids alone. Some of these differences may reflect underlying patient or inhibitor characteristics that led to these treatment choices.</p><p></p><p class="bulletIndent1">A 2021 retrospective review of 143 patients compared outcomes with several therapies and found an 80 percent response rate with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus glucocorticoids versus 35 percent response rate with glucocorticoids alone [<a href="#rid75">75</a>]. However, infections occurred in 39 percent of those receiving combination therapy, versus 11 percent with glucocorticoids alone. </p><p></p><p class="bulletIndent1">A 2012 analysis of 331 individuals in the EACH2 Registry with acquired hemophilia A found the following [<a href="#rid76">76</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete remission rate (factor VIII &gt;70 international units/dL and inhibitor undetectable off therapy)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cyclophosphamide plus a glucocorticoid: 66 of 83 (80 percent)</p><p class="bulletIndent3"><span class="glyph">-</span>Glucocorticoid alone: 83 of 142 (58 percent)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Median time to factor VIII &gt;70 international units/dL </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cyclophosphamide plus a glucocorticoid: 40 days</p><p class="bulletIndent3"><span class="glyph">-</span>Glucocorticoid alone: 32 days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Median time to stopping immunosuppression</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cyclophosphamide plus a glucocorticoid: 74 days</p><p class="bulletIndent3"><span class="glyph">-</span>Glucocorticoid alone: 108 days </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adverse events</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cyclophosphamide plus a glucocorticoid: 41 percent</p><p class="bulletIndent3"><span class="glyph">-</span>Glucocorticoid alone: 25 percent</p><p></p><p class="bulletIndent1">Another study found no difference in outcomes in individuals treated with cyclophosphamide plus a glucocorticoid versus a glucocorticoid alone [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rituximab</strong> – A randomized trial that compared a single dose of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> versus daily <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, in both cases added to <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> for three weeks followed by a taper, found similar rates of complete response (77 percent with rituximab versus 69 percent with cyclophosphamide) and adverse events [<a href="#rid72">72</a>]. Case reports and observational studies have described resolution of acquired hemophilia A in patients treated with rituximab [<a href="#rid77">77-86</a>]. One report from 2007 that analyzed 42 published cases of rituximab treatment and 44 cases of cyclophosphamide plus <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> treatment found complete response rates of 79 percent with rituximab (median time to response, 8.3 weeks) and 84 percent with cyclophosphamide plus prednisone (median time to response, 6.3 weeks) [<a href="#rid81">81</a>]. In a study that evaluated rituximab in four individuals with very high titer inhibitors (&gt;100 BU) whose disease did not respond to initial therapy with cyclophosphamide, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and prednisone but did respond after rituximab, the response was transient in three of the four [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CyDRi</strong> – A 2022 retrospective review of 32 patients with acquired hemophilia A treated with the CyDRi regimen reported complete remission in 31 (97 percent) [<a href="#rid74">74</a>]. The mean age was 74 years, and nine patients were &gt;80 years. The mean time to control of bleeding was 16 days (range, 0 to 429 days; median, 77 days). Adverse events were low and were reported to be milder than longer duration immunosuppressive regimens. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IVIG</strong> – Some case reports have described treatment of acquired hemophilia A with intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) [<a href="#rid64">64,73,87</a>]. In one prospective study that treated 19 patients with IVIG (1 g/kg for two days or 400 mg/kg IV for five days), there were six responses (32 percent), two within several days and four within weeks to months [<a href="#rid73">73</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other agents or combinations</strong> – In a series of 51 individuals with postpartum acquired hemophilia A, those who received <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, or <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a> had a shorter time to remission than those treated with glucocorticoids or no treatment [<a href="#rid17">17</a>]. Plasmapheresis for acquired factor inhibitors is considered a category III indication (role not established). (See  <a class="medical medical_review" href="/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology", section on 'ASFA therapeutic categories'</a>.)</p><p></p><p class="headingAnchor" id="H4097104424"><span class="h3">Spontaneous inhibitor resolution</span><span class="headingEndMark"> — </span>Spontaneous resolution may be more likely when the underlying condition also resolves. In a 1981 series of acquired hemophilia A, 11 of 31 individuals who received no immunosuppressive therapy had a spontaneous remission, at an average of 14 months after diagnosis [<a href="#rid16">16</a>]. Another study involving 16 individuals with acquired hemophilia A who received no immunosuppressive therapy reported spontaneous remission in five (31 percent) [<a href="#rid88">88</a>]. </p><p>However, some of the patients in these series have died of hemorrhage, and it is generally not advised to withhold immunosuppression with the hopes of spontaneous resolution. A possible exception is a very low titer inhibitor with no bleeding, in whom close observation without immunosuppression would be reasonable. </p><p class="headingAnchor" id="H621776"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Management of acquired hemophilia A during pregnancy is similar to non-pregnant individuals. The most relevant aspect of management is prevention and/or control of bleeding. Immunosuppression with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> may be used. Other agents are generally avoided unless maternal health is critically dependent on their use. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p>Involvement of the maternal fetal medicine expert in planning for labor and birth is essential.</p><p>The efficacy of therapy is monitored similarly to non-pregnant individuals. (See <a class="local">'Monitoring response to treatment'</a> below.)</p><p class="headingAnchor" id="H1382370"><span class="h2">Monitoring response to treatment</span><span class="headingEndMark"> — </span>The primary goal of treatment for an acquired factor inhibitor is cessation of bleeding, followed ultimately by a decrease in the titer of the inhibitor. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical monitoring</strong> – Cessation of bleeding is the most important outcome. For soft tissue bleeding, pain is a useful symptom to follow, as the pain often improves when the bleeding stops (even if there is residual hematoma). Since bleeding may be visceral, monitoring of the hemoglobin is especially important. Ongoing decrease in hemoglobin may warrant imaging to identify new visceral bleeding. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>aPTT, factor, and inhibitor assays</strong> – If the inhibitor causes a baseline prolongation of a clotting time, it may be possible to identify resolution of the inhibitor using standard clotting tests. The frequency of testing depends on the clinical picture (daily for active bleeding, less frequently if bleeding is absent or has resolved). </p><p></p><p class="bulletIndent1">We check the aPTT daily.</p><p></p><p class="bulletIndent1">We check the factor VIII activity and inhibitor titer once or twice per week initially, and then increase the interval, continuing until the aPTT and/or factor VIII activity normalize.</p><p></p><p class="bulletIndent1">An example monitoring schedule after the aPTT or factor VIII activity normalizes is to repeat testing monthly during the first six months, then once every two to three months for the first year, then every six months [<a href="#rid14">14</a>]. Laboratory testing can be discontinued after one year if the results are normal. The patient is advised to seek medical attention urgently for any symptom recurrence.</p><p></p><p class="bulletIndent1">An adequate response is complete absence of the inhibitor, which is the goal of treatment but not always achieved. We monitor inhibitor titers during immunosuppressive therapy. However, since inhibitor titers drop very slowly following successful treatment, it is neither necessary nor advisable to check the patient's aPTT or inhibitor titer more often than every two to four weeks once immunosuppressive therapy has been started. We also check a factor VIII activity level after approximately four weeks of immunosuppressive therapy to determine if factor activity is detectable.</p><p></p><p class="headingAnchor" id="H2518426184"><span class="h2">Thromboprophylaxis</span><span class="headingEndMark"> — </span>Individuals who remain hospitalized can resume thromboprophylaxis after the factor activity normalizes. (See  <a class="medical medical_review" href="/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a> and  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Prognosis/relapse risk</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response</strong> – Studies suggest that inhibitors associated with transient acquired conditions (pregnancy, infection, medications) are more likely to be eliminated [<a href="#rid7">7,32</a>]. Some studies have suggested that lower initial factor activity levels and higher initial inhibitor titers are associated with lower disease response rates [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Survival</strong> <em>– </em>Hemorrhagic death can occur, although the incidence has declined over time [<a href="#rid90">90</a>].</p><p></p><p>Outcomes are generally better in individuals with pregnancy or postpartum acquired hemophilia A, with nearly 100 percent survival. This may reflect the younger age, overall better health, and reversibility of the stimulus for the inhibitor [<a href="#rid20">20</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse</strong> – The relapse rate likely depends on whether the underlying condition persists. As an example, relapse rates of acquired hemophilia A associated with pregnancy are much lower than factor VIII inhibitors that are not pregnancy-related [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnancy</strong> – A review of nine individuals who had postpartum acquired hemophilia A found that none had recurrence with a subsequent pregnancy [<a href="#rid7">7</a>]. Relapse of pregnancy-associated acquired hemophilia A may rarely occur in subsequent pregnancies; the antibody may affect fetal factor VIII levels, resulting in life-threatening hemorrhage in a subsequent fetus because of transplacental transfer of IgG antibodies [<a href="#rid19">19,57,91,92</a>]. Patients with low antibody titers (ie, &lt;5 BU) tend to have remissions within months, whereas those with higher titers may have antibody persistence for years [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cancer</strong> – Case reports have described cancer-associated acquired hemophilia A that resolved after curative surgery [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1">Larger case series suggest a relapse rate for acquired hemophilia A following remission of approximately 20 percent [<a href="#rid45">45</a>]. Of individuals who experience a relapse, 70 percent will have a second complete remission.</p><p></p><p class="headingAnchor" id="H3946332370"><span class="h2">Treatment of relapse or refractory disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse </strong>– Relapses can be treated similarly to the initial episode if therapy was previously effective. (See <a class="local">'Control bleeding'</a> above and <a class="local">'Eliminate the inhibitor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory disease</strong> – Several options for immunosuppression are available for individuals with acquired factor inhibitors that do not resolve with the above treatments. (See <a class="local">'Eliminate the inhibitor'</a> above.)</p><p></p><p class="bulletIndent1">Examples are described in case reports.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="105443" href="/d/drug information/105443.html" rel="external">Daratumumab</a> [<a href="#rid94">94,95</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a> [<a href="#rid96">96-99</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">Cladribine</a> [<a href="#rid100">100</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> [<a href="#rid101">101</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>MMF [<a href="#rid101">101</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Plasmapheresis, with or without an immunoadsorption column to absorb the autoantibody [<a href="#rid34">34,102-105</a>]</p><p></p><p class="headingAnchor" id="H1852216219"><span class="h1">OTHER FACTOR INHIBITORS</span><span class="headingEndMark"> — </span>Acquired inhibitors to some factors are exceedingly rare and only described in case reports.</p><p class="headingAnchor" id="H2671060072"><span class="h2">Factor XIII inhibitors</span><span class="headingEndMark"> — </span>Activated factor XIII stabilizes and crosslinks overlapping fibrin strands in the fibrin clot. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Continuation of the coagulation cascade'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and pathogenesis</strong> – Factor XIII inhibitors are exceedingly rare. They can act by one of several mechanisms, including inhibiting factor XIII activation; interfering with enzymatic function; or preventing binding to fibrin [<a href="#rid106">106-108</a>]. </p><p></p><p class="bulletIndent1">Factor XIII inhibitors can be associated with immune dysregulation. A review from 2011 mentioned one-third of individuals had systemic lupus erythematosus [<a href="#rid109">109</a>]. A 2022 series of 97 patients identified the most common associated conditions as surgery (62 percent), cancer (41 percent), and liver disease (15 percent) [<a href="#rid110">110</a>]. Other associated conditions include other autoimmune disorders, lymphoid malignancies, and some drugs [<a href="#rid109">109,111</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – The clinical hallmark of a factor XIII inhibitor is delayed bleeding after surgery or an invasive procedure, since the initial clot is mechanically weak and unstable [<a href="#rid110">110</a>]. Large spontaneous hematomas or intracranial hemorrhage can occur. Hemorrhagic death from bleeding is not uncommon [<a href="#rid106">106,110,111</a>]. In a review of 33 cases, nine individuals died of hemorrhage [<a href="#rid111">111</a>]. </p><p></p><p class="bulletIndent1">The prothrombin time (PT) and activated partial thromboplastin time (aPTT) are normal, but clot solubility is abnormal [<a href="#rid111">111</a>]. D-dimer is not increased because formation of D-dimer requires factor XIIIa activity. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Clot solubility'</a> and  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Tests for defects in fibrin crosslinking or fibrinolysis'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management and prognosis</strong> – Most patients have been treated with immunosuppression and/or factor XIII concentrates [<a href="#rid111">111-116</a>]. </p><p></p><p class="headingAnchor" id="H2618172015"><span class="h2">Factor XI inhibitors</span><span class="headingEndMark"> — </span>Activated factor XI can activate factor IX, a component of the intrinsic X-ase, which in turn can activate factor X. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Multicomponent complexes'</a>.)</p><p>Acquired factor XI inhibitors in individuals without hemophilia B are often associated with systemic lupus erythematosus [<a href="#rid117">117,118</a>]. Affected patients usually have little or no bleeding despite a prolonged aPTT that does not fully correct in a mixing study. The relative lack of bleeding, which is also noted in congenital factor XI deficiency, probably reflects the tertiary role for factor XI in factor X activation, although bleeding can occur under certain circumstances. (See  <a class="medical medical_review" href="/d/html/1333.html" rel="external">"Factor XI (eleven) deficiency"</a>.)</p><p>Because factor XI deficiency carries less bleeding risk, close monitoring without immunosuppression is reasonable in a patient who is not bleeding.</p><p class="headingAnchor" id="H2672443519"><span class="h2">Factor X inhibitors</span><span class="headingEndMark"> — </span>Activated factor X cleaves prothrombin to thrombin in the final common pathway of clotting. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Thrombin generation'</a>.)</p><p>Acquired factor X inhibitors are extremely rare [<a href="#rid119">119-121</a>]. Antecedent acute respiratory infections have been noted. Presenting findings have included sudden onset bleeding, prolonged PT and aPTT, severe factor X deficiency. Inhibitors have not been conclusively demonstrated.</p><p>Amyloidosis can cause factor X deficiency due to factor X binding to amyloid fibrils [<a href="#rid122">122-125</a>]. (See  <a class="medical medical_review" href="/d/html/6668.html" rel="external">"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis", section on 'Clinical presentation'</a>.)</p><p>One well-characterized case of an acquired inhibitor involved the spontaneous appearance of an autoantibody in an older male who presented with hemoptysis, hematuria, and bleeding into the thigh after an intramuscular injection [<a href="#rid121">121</a>]. The patient was treated with glucocorticoids, and the inhibitor resolved within two weeks; it is not clear whether steroids contributed to inhibitor resolution. </p><p class="headingAnchor" id="H2804406112"><span class="h2">Factor IX inhibitors</span><span class="headingEndMark"> — </span>Activated factor IX is a component of the intrinsic X-ase, which can activate factor X. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Intrinsic or contact activation pathway'</a>.)</p><p>Acquired factor IX inhibitors in the absence of hemophilia B are also very rare; two cases have been reported in the postpartum period [<a href="#rid126">126-129</a>].</p><p>The role of immunosuppressive therapy is uncertain, but one child seemed to respond to <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid127">127</a>].</p><p class="headingAnchor" id="H574401388"><span class="h2">Factor VII inhibitors</span><span class="headingEndMark"> — </span>Activated factor VII is the primary initiator of blood clotting, via interaction with tissue factor in the extrinsic pathway of coagulation. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Extrinsic pathway'</a>.)</p><p>Acquired inhibitors of factor VII are rare, with only a small number of cases reported [<a href="#rid130">130-133</a>]. </p><p>Presenting findings have ranged from minor to life-threatening bleeding [<a href="#rid132">132,133</a>]. The aPTT is normal and the PT is prolonged. Mixing studies will confirm the presence of an inhibitor; a low level or absence of residual factor VII activity, especially after prolonged incubation (one hour) is necessary to confirm the diagnosis.</p><p>A case report described improvement with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, glucocorticoids, and plasma exchange, but not with <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> [<a href="#rid132">132</a>]. </p><p class="headingAnchor" id="H161517023"><span class="h2">Factor V inhibitors</span><span class="headingEndMark"> — </span>Activated factor V is a cofactor for factor Xa in activating prothrombin. Platelet factor V may be more important for assembly of the prothrombinase complex than circulating factor V [<a href="#rid134">134</a>]. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Thrombin generation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and pathogenesis</strong> – Most factor V inhibitors that arise from exposure to topical fibrin glues or bovine thrombin preparations that contain bovine factor V [<a href="#rid34">34,39,40,42</a>]. Some of the inhibitors crossreact with human factor V; typically, this applies to antibodies that recognize the C2 domain of factor V, which binds phospholipid phosphatidylserine on activated platelets and endothelial cells [<a href="#rid11">11-13</a>]. An acquired factor V inhibitor after exposure to topical human thrombin has also been reported [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1">One review evaluated 105 published cases of acquired factor V inhibitors found that 46 (44 percent) were associated with bovine thrombin exposure [<a href="#rid41">41</a>]. In a prospective study of patients treated with topical hemostatic agents, 13 of 34 (38 percent) developed factor V inhibitors, with more potent inhibitors after repeated exposures [<a href="#rid40">40</a>]. </p><p></p><p class="bulletIndent1">Other associated conditions included malignancy, autoimmune disease, the postpartum state, and congenital factor V deficiency. Nineteen had apparently idiopathic disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and evaluation</strong> – Bleeding manifestations associated with factor V inhibitors are variable, ranging from asymptomatic to life-threatening bleeding [<a href="#rid11">11,34,39,41</a>]. In one patient who did not have severe bleeding, the inhibitor neutralized circulating factor V but not platelet factor V [<a href="#rid135">135</a>]. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis"</a>.)</p><p></p><p class="bulletIndent1">Factor V inhibitors prolong the aPTT and PT but not the thrombin time (unless inhibitors of thrombin are also present) [<a href="#rid34">34</a>]. Factor V activity is decreased; mixing studies show failure to correct; and the inhibitor titer can be determined using the Bethesda assay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management and prognosis</strong> – Unlike bleeding for other inhibitors, treatment of bleeding for factor V inhibitors involves platelet transfusions; platelets contain factor V that is most important for clotting.</p><p></p><p class="bulletIndent1">Most inhibitors disappear within months; immunosuppression can be used, although it is not clear if immunosuppression accelerates resolution of the inhibitor. Close follow-up without immunosuppression is a reasonable approach as long as there is no active bleeding. For patients who survive the acute bleeding episode, the prognosis is generally excellent [<a href="#rid41">41</a>]. </p><p></p><p class="headingAnchor" id="H3030048710"><span class="h2">Factor II (prothrombin) and IIa (thrombin) inhibitors</span><span class="headingEndMark"> — </span>Factor II (prothrombin) is the precursor to thrombin (factor IIa), which converts fibrinogen to fibrin. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Overview of clot propagation'</a>.)</p><p>Antibodies against factor II can cause acquired factor II deficiency (associated with bleeding) or the lupus anticoagulant phenomenon (an in vitro effect). While antibodies against factor IIa have been detected, they are mostly clinically silent. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired factor II deficiency </strong>– Antibodies against prothrombin (factor II) can cause significant clinical bleeding since these antibodies usually cause accelerated clearance of prothrombin [<a href="#rid136">136</a>]. An autoantibody directed against prothrombin has been well characterized in one patient who did not have a lupus anticoagulant; it caused prothrombin depletion by a different epitope [<a href="#rid137">137</a>]. </p><p></p><p class="bulletIndent1">These antibodies may be suspected if a patient with antiphospholipid antibodies develops bleeding rather than thrombosis [<a href="#rid138">138,139</a>]. Specific immunochemical measurement of the prothrombin is required to establish the diagnosis.</p><p></p><p class="bulletIndent1">Treatment of active bleeding can include plasma (15 to 20 mL/kg), with a target prothrombin level &gt;30 percent, as well as other therapies described above [<a href="#rid137">137-140</a>]. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lupus anticoagulant</strong> – Antibodies to prothrombin can also occur in patients with antiphospholipid antibodies (aPL; specifically, antiphosphatidylserine antibodies) and contribute to the lupus anticoagulant effect [<a href="#rid136">136,138</a>]. This is an in vitro phenomenon that is not associated with clinical bleeding. (See  <a class="medical medical_review" href="/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome", section on 'Antiphospholipid antibodies'</a>.)</p><p></p><p class="headingAnchor" id="H1386911693"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119328.html" rel="external">"Society guideline links: Acquired bleeding disorders"</a>.) </p><p class="headingAnchor" id="H31"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis and incidence </strong>– Acquired factor inhibitors are polyclonal autoantibodies that inhibit clotting factor activity or (rarely) increase clearance. Approximately 50 percent have an underlying condition (cancer, autoimmune syndrome, postpartum). Acquired hemophilia A (acquired factor VIII inhibitor) is most common, affecting 1 to 2 per million annually. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect</strong> – Most patients present with bleeding (subcutaneous, retroperitoneal, intramuscular) and prolonged activated partial thromboplastin time (aPTT). Hemarthroses are rare. Inhibitors to factor V can develop after exposure to <a class="drug drug_general" data-topicid="10285" href="/d/drug information/10285.html" rel="external">topical thrombin</a> or fibrin glue. (See <a class="local">'Typical presentation and clinical findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – For individuals with bleeding and a prolonged aPTT, perform a mixing study and obtain factor VIII activity  (<a class="graphic graphic_algorithm graphicRef141723" href="/d/graphic/141723.html" rel="external">algorithm 1</a>). If an inhibitor is found, quantify the titer (Bethesda assay). If factor VIII activity is normal, evaluate for other factor deficiencies (IX, XI, XII, von Willebrand factor [VWF]). Other causes of bleeding with prolonged aPTT include heparin and other anticoagulants; antiphospholipid antibodies can prolong the aPTT without causing bleeding  (<a class="graphic graphic_table graphicRef79969" href="/d/graphic/79969.html" rel="external">table 2</a>). (See <a class="local">'Laboratory testing'</a> above and <a class="local">'Confirmed diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Patient with bleeding'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treating/prevent bleeding</strong> – A bleeding disorders expert should be consulted. Some patients may benefit from transfer to a tertiary center. (See <a class="local">'Control bleeding'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acquired hemophilia A </strong>–<strong> </strong>The flowchart summarizes our approach  (<a class="graphic graphic_algorithm graphicRef141724" href="/d/graphic/141724.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Bleeding</strong> – For individuals with acquired hemophilia A and active bleeding, we suggest a bypassing product rather than human factor VIII concentrates or other therapies (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The choice between factor eight inhibitor bypassing activity (FEIBA) and recombinant activated factor VII (rFVIIa) is individualized. Where available, <a class="drug drug_general" data-topicid="115772" href="/d/drug information/115772.html" rel="external">emicizumab</a> or porcine factor VIII is a reasonable alternative. Human factor VIII concentrates can be used if the inhibitor titer is &lt;5 Bethesda units (BU). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Not bleeding</strong> – The choice between hemostatic therapy versus close monitoring is individualized based on bleeding risk. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acquired factor V inhibitor</strong> – Bleeding may be treated with platelet transfusions. For bleeding that does not respond to platelet transfusions, we suggest a bypassing product (FEIBA or rFVIIa) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other inhibitors</strong> – Bleeding may be treated with factor concentrate if the inhibitor titer is &lt;5 BU. If factor concentrate is not available, plasma or (for factors II, VII, IX, and X) prothrombin complex concentrate (PCC) may be used. For bleeding with a higher titer inhibitor or that does not respond to these approaches, we suggest a bypassing product (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eliminate the inhibitor</strong> – Most patients with acquired hemophilia A have a high risk of life-threatening bleeding, and immunosuppressive therapy is usually required  (<a class="graphic graphic_algorithm graphicRef141724" href="/d/graphic/141724.html" rel="external">algorithm 2</a>). (See <a class="local">'Eliminate the inhibitor'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High titer inhibitor</strong> – For patients with inhibitor titer ≥5 BU, we suggest a glucocorticoid plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> or a glucocorticoid plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low titer inhibitor</strong> – For patients with inhibitor titer &lt;5 BU, we suggest <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For individuals with an inhibitor titer &lt;5 BU without bleeding, observation is a reasonable alternative. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Cessation of bleeding is the most important outcome; decreasing hemoglobin may be the only sign of visceral bleeding. Inhibitor resolution may be assessed by aPTT, factor activity, and/or inhibitor titer. Relapse rate for acquired hemophilia A is approximately 20 percent (lower for postpartum or with other transient conditions). (See <a class="local">'Monitoring response to treatment'</a> above and <a class="local">'Prognosis/relapse risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsed/refractory disease</strong> – Relapses can be retreated as the initial episode. Other immunosuppressive therapies may be needed for refractory disease. (See <a class="local">'Treatment of relapse or refractory disease'</a> above.)</p><p></p><p class="headingAnchor" id="H1633212409"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Steven Coutre, MD (deceased), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83:1978.</a></li><li><a class="nounderline abstract_t">Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86:1811.</a></li><li><a class="nounderline abstract_t">Pratt KP, Shen BW, Takeshima K, et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402:439.</a></li><li><a class="nounderline abstract_t">Mahendra A, Padiolleau-Lefevre S, Kaveri SV, Lacroix-Desmazes S. Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A? Br J Haematol 2012; 156:3.</a></li><li><a class="nounderline abstract_t">Irigoyen MB, Primiani L, Felippo M, et al. A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay. Haemophilia 2011; 17:267.</a></li><li><a class="nounderline abstract_t">Ling M, Duncan EM, Rodgers SE, et al. Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost 2003; 1:2548.</a></li><li><a class="nounderline abstract_t">Coller BS, Hultin MB, Hoyer LW, et al. Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis. Blood 1981; 58:619.</a></li><li><a class="nounderline abstract_t">Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69:1475.</a></li><li><a class="nounderline abstract_t">Prescott R, Nakai H, Saenko EL, et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997; 89:3663.</a></li><li><a class="nounderline abstract_t">Pavlova A, Zeitler H, Scharrer I, et al. HLA genotype in patients with acquired haemophilia A. Haemophilia 2010; 16:107.</a></li><li><a class="nounderline abstract_t">Ortel TL, Moore KD, Quinn-Allen MA, et al. Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations. Blood 1998; 91:4188.</a></li><li><a class="nounderline abstract_t">Ortel TL, Quinn-Allen MA, Charles LA, et al. Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity. J Clin Invest 1992; 90:2340.</a></li><li><a class="nounderline abstract_t">Macedo-Ribeiro S, Bode W, Huber R, et al. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature 1999; 402:434.</a></li><li><a class="nounderline abstract_t">Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 2020; 105:1791.</a></li><li><a class="nounderline abstract_t">Franchini M, Mannucci PM. Acquired haemophilia A: a 2013 update. Thromb Haemost 2013; 110:1114.</a></li><li><a class="nounderline abstract_t">Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45:200.</a></li><li><a class="nounderline abstract_t">Hauser I, Schneider B, Lechner K. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost 1995; 73:1.</a></li><li><a class="nounderline abstract_t">Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10:622.</a></li><li><a class="nounderline abstract_t">Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol 2006; 81:768.</a></li><li><a class="nounderline abstract_t">Tengborn L, Baudo F, Huth-Kühne A, et al. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG 2012; 119:1529.</a></li><li><a class="nounderline abstract_t">Michiels JJ. Acquired hemophilia A in women postpartum: clinical manifestations, diagnosis, and treatment. Clin Appl Thromb Hemost 2000; 6:82.</a></li><li><a class="nounderline abstract_t">Hauser I, Lechner K. Solid tumors and factor VIII antibodies. Thromb Haemost 1999; 82:1005.</a></li><li><a class="nounderline abstract_t">Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer 2001; 91:1067.</a></li><li><a class="nounderline abstract_t">Soriano RM, Matthews JM, Guerado-Parra E. Acquired haemophilia and rheumatoid arthritis. Br J Rheumatol 1987; 26:381.</a></li><li><a class="nounderline abstract_t">Konstantinov K, Dolladille C, Gillet B, et al. Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database. Haemophilia 2023; 29:186.</a></li><li><a class="nounderline abstract_t">Tiplady CW, Hamilton PJ, Galloway MJ. Acquired haemophilia complicating the remission of a patient with high grade non-Hodgkin's lymphoma treated by fludarabine. Clin Lab Haematol 2000; 22:163.</a></li><li><a class="nounderline abstract_t">English KE, Brien WF, Howson-Jan K, Kovacs MJ. Acquired factor VIII inhibitor in a patient with chronic myelogenous leukemia receiving interferon-alfa therapy. Ann Pharmacother 2000; 34:737.</a></li><li><a class="nounderline abstract_t">Komminoth A, Dufour P, Bergerat JP, et al. Hairy cell leukemia and factor VIII inhibitor: a case report. Nouv Rev Fr Hematol 1992; 34:269.</a></li><li><a class="nounderline abstract_t">Sallah S, Wan JY. Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine. Thromb Haemost 2001; 86:1119.</a></li><li><a class="nounderline abstract_t">Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011; 365:1747.</a></li><li><a class="nounderline abstract_t">Moore DC, Elmes JB, Arnall JR, et al. Immune checkpoint inhibitor-induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system. Haemophilia 2022; 28:e145.</a></li><li><a class="nounderline abstract_t">Franchini M, Zaffanello M, Lippi G. Acquired hemophilia in pediatrics: a systematic review. Pediatr Blood Cancer 2010; 55:606.</a></li><li><a class="nounderline abstract_t">Pilania RK, Suri D, Jindal AK, et al. Lupus anticoagulant hypoprothrombinemia syndrome associated with systemic lupus erythematosus in children: report of two cases and systematic review of the literature. Rheumatol Int 2018; 38:1933.</a></li><li><a class="nounderline abstract_t">Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76:2011.</a></li><li><a class="nounderline abstract_t">LOELIGER A, HERS JF. Chronic antithrombinaemia (Antithrombin V) with Haemorrhagic diathesis in a case of rheumatoid arthritis with hypergammaglobulinaemia). Thromb Diath Haemorrh 1957; 1:499.</a></li><li><a class="nounderline abstract_t">Scully MF, Ellis V, Kakkar VV, et al. An acquired coagulation inhibitor to factor II. Br J Haematol 1982; 50:655.</a></li><li><a class="nounderline abstract_t">Gabriel DA, Carr ME, Cook L, Roberts HR. Spontaneous antithrombin in a patient with benign paraprotein. Am J Hematol 1987; 25:85.</a></li><li><a class="nounderline abstract_t">Flaherty MJ, Henderson R, Wener MH. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Ann Intern Med 1989; 111:631.</a></li><li><a class="nounderline abstract_t">Ortel TL, Charles LA, Keller FG, et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol 1994; 45:128.</a></li><li><a class="nounderline abstract_t">Bänninger H, Hardegger T, Tobler A, et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 1993; 85:528.</a></li><li><a class="nounderline abstract_t">Knöbl P, Lechner K. Acquired factor V inhibitors. Baillieres Clin Haematol 1998; 11:305.</a></li><li><a class="nounderline abstract_t">Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002; 42:18.</a></li><li><a class="nounderline abstract_t">Donohoe K, Levine R. Acquired factor V inhibitor after exposure to topical human thrombin related to an otorhinolaryngological procedure. J Thromb Haemost 2015; 13:1787.</a></li><li><a class="nounderline abstract_t">Collins P, Macartney N, Davies R, et al. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol 2004; 124:86.</a></li><li><a class="nounderline abstract_t">Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109:1870.</a></li><li><a class="nounderline abstract_t">Tian C, Perija B, Kotb R, et al. Acquired haemophilia A: A 15-year population-based review of incidence rate, patient demographics and treatment outcomes. Haemophilia 2023; 29:1269.</a></li><li><a class="nounderline abstract_t">Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121:21.</a></li><li><a class="nounderline abstract_t">La Spada AR, Skålhegg BS, Henderson R, et al. Brief report: fatal hemorrhage in a patient with an acquired inhibitor of human thrombin. N Engl J Med 1995; 333:494.</a></li><li><a class="nounderline abstract_t">Dewarrat N, Gavillet M, Angelillo-Scherrer A, et al. Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review. Haemophilia 2021; 27:199.</a></li><li><a class="nounderline abstract_t">Lossing TS, Kasper CK, Feinstein DI. Detection of factor VIII inhibitors with the partial thromboplastin time. Blood 1977; 49:793.</a></li><li><a class="nounderline abstract_t">Kasper CK, Aledort L, Aronson D, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34:612.</a></li><li><a class="nounderline abstract_t">Kessler CM, Knöbl P. Acquired haemophilia: an overview for clinical practice. Eur J Haematol 2015; 95 Suppl 81:36.</a></li><li><a class="nounderline abstract_t">Werwitzke S, Geisen U, Nowak-Göttl U, et al. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study. J Thromb Haemost 2016; 14:940.</a></li><li><a class="nounderline abstract_t">Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007; 5:893.</a></li><li><a class="nounderline abstract_t">Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol 2010; 148:183.</a></li><li><a class="nounderline abstract_t">Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol 2005; 80:55.</a></li><li><a class="nounderline abstract_t">Hay CR, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133:591.</a></li><li><a class="nounderline abstract_t">Liebman HA, Chediak J, Fink KI, et al. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol 2000; 63:109.</a></li><li><a class="nounderline abstract_t">Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10:169.</a></li><li><a class="nounderline abstract_t">Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 78:1463.</a></li><li><a class="nounderline abstract_t">Baudo F, Collins P, Huth-Kühne A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120:39.</a></li><li><a class="nounderline abstract_t">Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015; 21:162.</a></li><li><a class="nounderline abstract_t">Huth-Kühne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94:566.</a></li><li><a class="nounderline abstract_t">Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112:250.</a></li><li><a class="nounderline abstract_t">Pfrepper C, Klamroth R, Oldenburg J, et al. Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group. Hamostaseologie 2023.</a></li><li><a class="nounderline abstract_t">Shima M, Amano K, Ogawa Y, et al. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost 2023; 21:534.</a></li><li><a class="nounderline abstract_t">Chen EC, Gibson W, Temoczko P, et al. Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single-institution experience. Haemophilia 2023; 29:84.</a></li><li><a class="nounderline abstract_t">Knoebl P, Thaler J, Jilma P, et al. Emicizumab for the treatment of acquired hemophilia A. Blood 2021; 137:410.</a></li><li><a class="nounderline abstract_t">Engelen MM, Vandesande J, De Bent J, et al. Emicizumab for acquired haemophilia A: A case series. Haemophilia 2023; 29:1049.</a></li><li class="breakAll">OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence]
Lyophilized Powder for Solution for Intravenous Injection. US Food &amp; Drug Administration (FDA) approved product information. Available at: https://www.fda.gov/media/89987/download (Accessed on March 23, 2023).</li><li><a class="nounderline abstract_t">Zakas PM, Vanijcharoenkarn K, Markovitz RC, et al. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors. J Thromb Haemost 2015; 13:72.</a></li><li><a class="nounderline abstract_t">Wang P, Zhou R, Xue F, et al. Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferiority trial. Am J Hematol 2024; 99:28.</a></li><li><a class="nounderline abstract_t">Schwartz RS, Gabriel DA, Aledort LM, et al. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 1995; 86:797.</a></li><li><a class="nounderline abstract_t">Simon B, Ceglédi A, Dolgos J, et al. Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen. Blood 2022; 140:1983.</a></li><li><a class="nounderline abstract_t">Schep SJ, van Dijk WEM, Beckers EAM, et al. Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study. Am J Hematol 2021; 96:51.</a></li><li><a class="nounderline abstract_t">Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120:47.</a></li><li><a class="nounderline abstract_t">Wiestner A, Cho HJ, Asch AS, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100:3426.</a></li><li><a class="nounderline abstract_t">Kain S, Copeland TS, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol 2002; 119:578.</a></li><li><a class="nounderline abstract_t">Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103:4424.</a></li><li><a class="nounderline abstract_t">Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol 2007; 63:47.</a></li><li><a class="nounderline abstract_t">Sperr WR, Lechner K, Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 2007; 92:66.</a></li><li><a class="nounderline abstract_t">Field JJ, Fenske TS, Blinder MA. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia 2007; 13:46.</a></li><li><a class="nounderline abstract_t">Franchini M, Veneri D, Lippi G, Stenner R. The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost 2006; 96:119.</a></li><li><a class="nounderline abstract_t">Onitilo AA, Skorupa A, Lal A, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost 2006; 96:84.</a></li><li><a class="nounderline abstract_t">Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008; 141:149.</a></li><li><a class="nounderline abstract_t">Boles JC, Key NS, Kasthuri R, Ma AD. Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia. J Thromb Haemost 2011; 9:1429.</a></li><li><a class="nounderline abstract_t">Lafferty TE, Smith JB, Schuster SJ, DeHoratius RJ. Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40:775.</a></li><li><a class="nounderline abstract_t">Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147:1077.</a></li><li><a class="nounderline abstract_t">Tiede A, Klamroth R, Scharf RE, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015; 125:1091.</a></li><li><a class="nounderline abstract_t">Baudo F, de Cataldo F. The problem of acquired hemophilia. Blood 2015; 125:1052.</a></li><li><a class="nounderline abstract_t">Scully MF, Shublaq W, Oliver GD. Acquired hemophilia a presenting as a bleeding diathesis in a postpartum patient: diagnosis and management. J Obstet Gynaecol Can 2002; 24:430.</a></li><li><a class="nounderline abstract_t">Mytopher K, Dudebout J, Card R, Gilliland B. Acquired hemophilia A presenting post partum. CMAJ 2007; 177:339.</a></li><li><a class="nounderline abstract_t">Shurafa M, Raman S, Wollner I. Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma. Am J Hematol 1995; 50:149.</a></li><li><a class="nounderline abstract_t">Liu W, Liu J, Xue F, et al. Anti-CD38 antibody for refractory acquired hemophilia A. J Thromb Haemost 2023; 21:1515.</a></li><li><a class="nounderline abstract_t">Moonla C, Polprasert C, Krittikarux S, et al. Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers. Haemophilia 2023; 29:1649.</a></li><li><a class="nounderline abstract_t">Schulman S, Langevitz P, Livneh A, et al. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost 1996; 76:344.</a></li><li><a class="nounderline abstract_t">Brox AG, Laryea H, Pelletier M. Successful treatment of acquired factor VIII inhibitors with cyclosporin. Am J Hematol 1998; 57:87.</a></li><li><a class="nounderline abstract_t">Maclean PS, Tait RC, Lowe GD, et al. Successful elimination of factor VIII inhibitor using cyclosporin A. Br J Haematol 2003; 122:1024.</a></li><li><a class="nounderline abstract_t">Petrovic M, Derom E, Baele G. Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies. Haematologica 2000; 85:895.</a></li><li><a class="nounderline abstract_t">Sallah S, Wan JY. Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia. Blood 2003; 101:943.</a></li><li><a class="nounderline abstract_t">Wu JF, Malec LM, Pandit S, et al. A 10-year single-institution retrospective review of treatment for acquired hemophilia A. Haemophilia 2023; 29:1656.</a></li><li><a class="nounderline abstract_t">Kessler CM. New perspectives in hemophilia treatment. Hematology Am Soc Hematol Educ Program 2005; :429.</a></li><li><a class="nounderline abstract_t">Jansen M, Schmaldienst S, Banyai S, et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001; 112:91.</a></li><li><a class="nounderline abstract_t">Freedman J, Rand ML, Russell O, et al. Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion 2003; 43:1508.</a></li><li><a class="nounderline abstract_t">Zeitler H, Ulrich-Merzenich G, Hess L, et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 2005; 105:2287.</a></li><li class="breakAll">Lorand L. Acquired inhibitors of fibrin stabilization: A class of hemorrhagic disorders of diverse origins. In: Anticoagulants: Physiologic, Pathologic and Pharmacologic, Green D (Ed), CRC Press, Cleveland 1994. p.169.</li><li><a class="nounderline abstract_t">Tosetto A, Castaman G, Rodeghiero F. Acquired plasma factor XIII deficiencies. Haematologica 1993; 78:5.</a></li><li><a class="nounderline abstract_t">Nixon CP, Prsic EH, Guertin CA, et al. Acquired Factor XIII inhibitor associated with mantle cell lymphoma. Transfusion 2017; 57:694.</a></li><li><a class="nounderline abstract_t">Kohler HP, Ichinose A, Seitz R, et al. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9:1404.</a></li><li><a class="nounderline abstract_t">Duque P, Chasco-Ganuza M, Ortuzar A, et al. Acquired FXIII Deficiency is Associated with High Morbidity. Thromb Haemost 2022; 122:48.</a></li><li><a class="nounderline abstract_t">Boehlen F, Casini A, Chizzolini C, et al. Acquired factor XIII deficiency: a therapeutic challenge. Thromb Haemost 2013; 109:479.</a></li><li><a class="nounderline abstract_t">Nakamura S, Kato A, Sakata Y, Aoki N. Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide. Br J Haematol 1988; 68:313.</a></li><li><a class="nounderline abstract_t">Daly HM, Carson PJ, Smith JK. Intracerebral haemorrhage due to acquired factor XIII inhibitor--successful response to factor XIII concentrate. Blood Coagul Fibrinolysis 1991; 2:507.</a></li><li><a class="nounderline abstract_t">Tosetto A, Rodeghiero F, Gatto E, et al. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. Am J Hematol 1995; 48:34.</a></li><li><a class="nounderline abstract_t">Ajzner E, Schlammadinger A, Kerényi A, et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood 2009; 113:723.</a></li><li><a class="nounderline abstract_t">Ichinose A, Souri M, Japanese collaborative research group on "Acquired haemorrha-philia due to factor XIII deficiency". As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 2011; 105:925.</a></li><li><a class="nounderline abstract_t">Reece EA, Clyne LP, Romero R, Hobbins JC. Spontaneous factor XI inhibitors. Seven additional cases and a review of the literature. Arch Intern Med 1984; 144:525.</a></li><li><a class="nounderline abstract_t">Vercellotti GM, Mosher DF. Acquired factor XI deficiency in systemic lupus erythematosus. Thromb Haemost 1982; 48:250.</a></li><li><a class="nounderline abstract_t">Mulhare PE, Tracy PB, Golden EA, et al. A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X. Am J Clin Pathol 1991; 96:196.</a></li><li><a class="nounderline abstract_t">Lankiewicz MW, Bell WR. A unique circulating inhibitor with specificity for coagulation factor X. Am J Med 1992; 93:343.</a></li><li><a class="nounderline abstract_t">Rao LV, Zivelin A, Iturbe I, Rapaport SI. Antibody-induced acute factor X deficiency: clinical manifestations and properties of the antibody. Thromb Haemost 1994; 72:363.</a></li><li><a class="nounderline abstract_t">Furie B, Greene E, Furie BC. Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X. N Engl J Med 1977; 297:81.</a></li><li><a class="nounderline abstract_t">Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001; 97:1885.</a></li><li><a class="nounderline abstract_t">Ericson S, Shah N, Liberman J, Aboulafia DM. Fatal bleeding due to acquired factor IX and X deficiency: a rare complication of primary amyloidosis; case report and review of the literature. Clin Lymphoma Myeloma Leuk 2014; 14:e81.</a></li><li><a class="nounderline abstract_t">Mumford AD, O'Donnell J, Gillmore JD, et al. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol 2000; 110:454.</a></li><li><a class="nounderline abstract_t">Miller K, Neely JE, Krivit W, Edson JR. Spontaneously acquired factor IX inhibitor in a nonhemophiliac child. J Pediatr 1978; 93:232.</a></li><li><a class="nounderline abstract_t">Mazzucconi MG, Peraino M, Bizzoni L, et al. Acquired inhibitor against factor IX in a child: successful treatment with high-dose immunoglobulin and dexamethasone. Haemophilia 1999; 5:132.</a></li><li><a class="nounderline abstract_t">Largo R, Sigg P, von Felten A, Straub PW. Acquired factor-IX inhibitor in a nonhaemophilic patient with autoimmune disease. Br J Haematol 1974; 26:129.</a></li><li><a class="nounderline abstract_t">Berman BW, McIntosh S, Clyne LP, et al. Spontaneously acquired Factor IX inhibitors in childhood. Am J Pediatr Hematol Oncol 1981; 3:77.</a></li><li><a class="nounderline abstract_t">Campbell E, Sanal S, Mattson J, et al. Factor VII inhibitor. Am J Med 1980; 68:962.</a></li><li><a class="nounderline abstract_t">Weisdorf D, Hasegawa D, Fair DS. Acquired factor VII deficiency associated with aplastic anaemia: correction with bone marrow transplantation. Br J Haematol 1989; 71:409.</a></li><li><a class="nounderline abstract_t">Delmer A, Horellou MH, Andreu G, et al. Life-threatening intracranial bleeding associated with the presence of an antifactor VII autoantibody. Blood 1989; 74:229.</a></li><li><a class="nounderline abstract_t">Okajima K, Ishii M. Life-threatening bleeding in a case of autoantibody-induced factor VII deficiency. Int J Hematol 1999; 69:129.</a></li><li><a class="nounderline abstract_t">Tracy PB, Giles AR, Mann KG, et al. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest 1984; 74:1221.</a></li><li><a class="nounderline abstract_t">Nesheim ME, Nichols WL, Cole TL, et al. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 1986; 77:405.</a></li><li><a class="nounderline abstract_t">Bajaj SP, Rapaport SI, Fierer DS, et al. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983; 61:684.</a></li><li><a class="nounderline abstract_t">Bajaj SP, Rapaport SI, Barclay S, Herbst KD. Acquired hypoprothrombinemia due to non-neutralizing antibodies to prothrombin: mechanism and management. Blood 1985; 65:1538.</a></li><li><a class="nounderline abstract_t">Vivaldi P, Rossetti G, Galli M, Finazzi G. Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica 1997; 82:345.</a></li><li><a class="nounderline abstract_t">Erkan D, Bateman H, Lockshin MD. Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature. Lupus 1999; 8:560.</a></li><li><a class="nounderline abstract_t">Huang LW, Anand S, Hassan S, Onwuemene O. Bruised Black and Blue: Acquired Hypoprothrombinemia. Am J Med 2015; 128:e7.</a></li></ol></div><div id="topicVersionRevision">Topic 1305 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2498393" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7544643" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10586887" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Structure of the C2 domain of human factor VIII at 1.5 A resolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21988190" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21070488" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14675091" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6789845" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2436689" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9160671" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20536993" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : HLA genotype in patients with acquired haemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9596666" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1281831" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10586886" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Crystal structures of the membrane-binding C2 domain of human coagulation factor V.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32381574" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : International recommendations on the diagnosis and treatment of acquired hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24008306" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acquired haemophilia A: a 2013 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6792737" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A survey of 215 non-hemophilic patients with inhibitors to Factor VIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7740477" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22321904" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868941" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Postpartum acquired factor VIII inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22901076" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10775027" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acquired hemophilia A in women postpartum: clinical manifestations, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10494753" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Solid tumors and factor VIII antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11267950" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3117157" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acquired haemophilia and rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36367755" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931166" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acquired haemophilia complicating the remission of a patient with high grade non-Hodgkin's lymphoma treated by fludarabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10860135" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acquired factor VIII inhibitor in a patient with chronic myelogenous leukemia receiving interferon-alfa therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1408738" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hairy cell leukemia and factor VIII inhibitor: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11686336" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22047582" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hemophilia A induced by ipilimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35895993" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Immune checkpoint inhibitor-induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20589621" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Acquired hemophilia in pediatrics: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30099593" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Lupus anticoagulant hypoprothrombinemia syndrome associated with systemic lupus erythematosus in children: report of two cases and systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2242423" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13581008" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Chronic antithrombinaemia (Antithrombin V) with Haemorrhagic diathesis in a case of rheumatoid arthritis with hypergammaglobulinaemia).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7066212" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : An acquired coagulation inhibitor to factor II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3578266" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Spontaneous antithrombin in a patient with benign paraprotein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2802417" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8141118" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8136275" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10097809" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Acquired factor V inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11896308" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26270511" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Acquired factor V inhibitor after exposure to topical human thrombin related to an otorhinolaryngological procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14675412" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A population based, unselected, consecutive cohort of patients with acquired haemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17047148" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37639377" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Acquired haemophilia A: A 15-year population-based review of incidence rate, patient demographics and treatment outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12670328" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7623881" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Brief report: fatal hemorrhage in a patient with an acquired inhibitor of human thrombin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33550699" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/856360" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Detection of factor VIII inhibitors with the partial thromboplastin time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1198543" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Proceedings: A more uniform measurement of factor VIII inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679396" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Acquired haemophilia: an overview for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26988717" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17461924" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of acquired hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19814739" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Advances in the understanding of acquired haemophilia A: implications for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16138334" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Acquired hemophilia A: a concise review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16704433" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10679799" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14962206" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of acquired haemophilia with factor eight inhibitor bypassing activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9423795" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22618709" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25623166" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19336751" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : International recommendations on the diagnosis and treatment of patients with acquired hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18463353" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Acquired factor VIII inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38049124" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36696195" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36163651" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32766881" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Emicizumab for the treatment of acquired hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37276345" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Emicizumab for acquired haemophilia A: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37276345" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Emicizumab for acquired haemophilia A: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25315236" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37851608" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7606010" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35930747" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32974947" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22517903" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384448" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Rituximab in the treatment of acquired factor VIII inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406107" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996701" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17236786" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Rituximab in the treatment of adult acquired hemophilia A: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229637" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Rituximab for the treatment of acquired antibodies to factor VIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17212724" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894452" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16807656" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Rituximab in the treatment of acquired factor VIII inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18318765" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Rituximab in the treatment of autoimmune haematological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21575131" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9125263" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3109341" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25525118" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25678432" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The problem of acquired hemophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196864" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Acquired hemophilia a presenting as a bleeding diathesis in a postpartum patient: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698819" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Acquired hemophilia A presenting post partum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573000" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36940802" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Anti-CD38 antibody for refractory acquired hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37665794" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8883268" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9423825" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Successful treatment of acquired factor VIII inhibitors with cyclosporin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12956775" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Successful elimination of factor VIII inhibitor using cyclosporin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942956" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393474" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37694801" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A 10-year single-institution retrospective review of treatment for acquired hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16304415" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : New perspectives in hemophilia treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11167789" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14617307" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15542586" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15542586" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8039759" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Acquired plasma factor XIII deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27917497" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Acquired Factor XIII inhibitor associated with mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22946956" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Diagnosis and classification of factor XIII deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33851388" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Acquired FXIII Deficiency is Associated with High Morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23306660" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Acquired factor XIII deficiency: a therapeutic challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3258529" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1768763" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Intracerebral haemorrhage due to acquired factor XIII inhibitor--successful response to factor XIII concentrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7832189" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18955560" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21264450" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6703824" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Spontaneous factor XI inhibitors. Seven additional cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7164014" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Acquired factor XI deficiency in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1862774" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1524089" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : A unique circulating inhibitor with specificity for coagulation factor X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7855785" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Antibody-induced acute factor X deficiency: clinical manifestations and properties of the antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/865580" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238135" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24290671" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Fatal bleeding due to acquired factor IX and X deficiency: a rare complication of primary amyloidosis; case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10971408" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/671155" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Spontaneously acquired factor IX inhibitor in a nonhemophiliac child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10215963" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Acquired inhibitor against factor IX in a child: successful treatment with high-dose immunoglobulin and dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4211775" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Acquired factor-IX inhibitor in a nonhaemophilic patient with autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7235194" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Spontaneously acquired Factor IX inhibitors in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7386495" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Factor VII inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2649142" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Acquired factor VII deficiency associated with aplastic anaemia: correction with bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2752111" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Life-threatening intracranial bleeding associated with the presence of an antifactor VII autoantibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071464" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Life-threatening bleeding in a case of autoantibody-induced factor VII deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6480825" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3944265" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Isolation and study of an acquired inhibitor of human coagulation factor V.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6403077" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3995183" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Acquired hypoprothrombinemia due to non-neutralizing antibodies to prothrombin: mechanism and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9234588" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10483036" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26159638" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Bruised Black and Blue: Acquired Hypoprothrombinemia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
